tuftsin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
=== Center for Biosecurity at UPMC === The Center for Biosecurity at UPMC (CBUPMC) is led by Thomas V. Inglesby, MD. Their mandate is to conduct "independent research, analysis, and nonpartisan policy recommendations" to serve as "resources for decision makers who are responsible for strengthening US planning, response, and resilience to catastrophic events."
Pentazocine, sold under the brand name Talwin among others, is an opioid analgesic medication used to treat moderate to severe pain. Pentazocine activates (agonizes) κ-opioid receptors (KOR) and μ-opioid receptors (MOR). It shares many of the side effects of other opioids like constipation, nausea, itching, drowsiness, and respiratory depression, but, unlike most other opioids, it fairly frequently causes hallucinations, nightmares, and delusions. It is also, unlike most other opioids, subject to a ceiling effect, which is when at a certain dose no more pain relief is obtained by increasing the dose any further. Chemically it is classed as a benzomorphan and it comes in two enantiomers. It was patented in 1960 and approved for medical use in 1964. Usually, in its oral formulations, it is combined with naloxone so as to prevent people from crushing the tablets, dissolving them in saline and injecting them for a high (as orally administered naloxone produces no opioid-negating effects as it has no oral bioavailability, whereas intravenous or intramuscular administration does).
While most definitions of tissue engineering cover a broad range of applications, in practice, the term is closely associated with applications that repair or replace portions of or whole tissues (i.e. organs, bone, cartilage, blood vessels, bladder, skin, muscle etc.). Often, the tissues involved require certain mechanical and structural properties for proper functioning. The term has also been applied to efforts to perform specific biochemical functions using cells within an artificially created support system (e.g. an artificial pancreas, or a bio artificial liver). The term regenerative medicine is often used synonymously with tissue engineering, although those involved in regenerative medicine place more emphasis on the use of stem cells or progenitor cells to produce tissues.
Transgender people face various kinds of discrimination, especially in health care situations. An assessment of transgender needs in Philadelphia found that 26% of respondents had been denied health care because they were transgender and 52% of respondents had difficulty accessing health services. Aside from transition related care, transgender and gender non-conforming individuals need preventive care such as vaccines, gynecological care, prostate exams, and other annual preventive health measures. Various factors play a role in creating the limited access to care, such as insurance coverage issues related to their legal gender identity status. The Affordable Care Act (commonly known as Obamacare) marketplace has improved access to insurance for the LGBTQ community through anti-discriminatory measures, such as not allowing insurance companies to reject consumers for being transgender. However, insurance sold outside of the ACA marketplace does not have to follow these requirements. This means that preventive care, such as gynecological exams for transgender men, may not be covered. Starting in the early-2020s, as many as 13 U.S. states banned gender affirming health care for transgender youth, with several states further restricting treatment for adults as well. In January 2024, several Republican legislators have expressed their desire to ban gender-affirming healthcare altogether.
Sources: en.wikipedia.org
Chain brake A chain brake activator is located forward of the upper handle and is activated by a kickback event. When triggered, it tensions a band around the clutch drum, stopping the chain within milliseconds. A chain catcher is located between the saw body and the clutch cover. In most cases, it resembles a hook made of aluminum. It is used to stop the chain when it derails from the bar and shortens the length of the chain. When derailing, the chain swings from underneath the saw towards the operator. This prevents the chain from hitting the operator, which hits the rear handle guard instead. A rear handle guard protects the hand of the operator when the chain derails. Some chains have safety links, as on micro chisel saws. These links keep the saw close to the gap between two cutting links and lift the chain when the space at the safety link is full with saw chips, which lifts the chain and lets it cut slower. Nonprofessional chains have less aggressive teeth, by having shallower depth gauges.
Trump further announced that month a plan for a new fleet of naval vessels, to be called Trump-class battleships, although battleships have long been obsolete in naval warfare and the Navy's last one in service was decommissioned in 1992. For many years, the National Park Service's annual general pass depicted natural landscapes, but the new 2026 pass design for U.S. residents has a photo of Donald Trump. The redesign triggered a popular backlash of passholders' covering his photo with stickers; the Park Service responded by updating its ban on defaced passes to include anything obscuring the front. The year also marked the Treasury's announcement that Trump's own signature would replace that of the treasurer on paper currency, another first for a president; the State Department’s issuance of a new passport design with a portrait of Trump, the first living president to appear on a U.S. passport, offered as an option to in-person applicants at the Washington, D.C., Passport Agency; and Florida Gov. Ron DeSantis's consent to renaming Palm Beach International Airport after Trump, a change the president had reportedly sought in 2020. Other measures bearing Trump’s name are Trump accounts, tax-advantaged investment accounts for American minors rolled out as part of the One Big Beautiful Bill Act; TrumpRx, a prescription drug website run by the federal government; and the Trump Gold Card, a program offering foreign nationals expedited U.S. residency in exchange for donations of $1 million or more to the Commerce Department and denounced by U.S. Sen.
== Th22 in diseases == Th22 has both pathologic and protective claimed roles when maintaining immunologic homeostasis. However, the role of Th22 in pathological processes has not been completely identified.
Sources: en.wikipedia.org
Channa amari Dey et al., 2019 — likely a synonym of C. brunnea Channa amphibeus (McClelland, 1845) (Borna snakehead) Channa andrao Britz, 2013 Channa ara (Deraniyagala, 1945) Channa argus (Cantor, 1842) (northern snakehead) Channa aristonei Praveenraj, Thackeray, Singh, Uma, Moulitharan & Mukhim, 2020 Channa asiatica (Linnaeus, 1758) (small snakehead) Channa aurantimaculata Musikasinthorn, 2000 (orange-spotted snakehead) Channa aurantipectoralis Lalhlimpuia, Lalronunga & Lalramliana, 2016 Channa auroflammea Adamson, Britz and S. Lieng, 2019 Channa aurolineata (F. Day, 1870) Channa bankanensis (Bleeker, 1853) Channa baramensis (Steindachner, 1901) Channa barca (F. Hamilton, 1822) (barca snakehead) Channa bipuli Praveenraj, Uma, Moulitharan & Bleher, 2018 Channa bleheri Vierke, 1991 (rainbow snakehead) Channa brahmacharyi Chakraborty, Yardi & Mukherjee, 2020 Channa brunnea Praveenraj, Uma, Moulitharan & Kannan, 2019 Channa burmanica B. L. Chaudhuri, 1919 Channa coccinea Britz, H. H. Tan & Rüber, 2024 Channa cyanospilos (Bleeker, 1853) Channa diplogramma (F. Day, 1865) (Malabar snakehead) Channa gachua (F. Hamilton, 1822) (dwarf snakehead) Channa harcourtbutleri (Annandale, 1918) (Burmese snakehead) Channa hoaluensis Nguyen, 2011 Channa kelaartii (Günther, 1861) Channa limbata (Cuvier, 1831) Channa lipor Praveenraj, Uma, Moulitharan & Singh, 2019 Channa longistomata (Nguyen & Nguyen, 2012) Channa lucius (G. Cuvier, 1831) (forest snakehead) Channa maculata (Lacépède, 1801) (blotched snakehead) Channa marulioides (Bleeker, 1851) (emperor snakehead) Channa marulius (F.
=== Aquaculture === Methylene blue is used in aquaculture and by tropical fish hobbyists as a treatment for fungal infections. With the help of light, it is also effective against bacteria and viruses. It can also be effective in treating fish infected with the parasitic protozoa Ichthyophthirius multifiliis (ich), although a combination of malachite green and formaldehyde is far more effective against it. Methylene blue also works against nitrite poisoning as it treats the resulting methemoglobinemia. Like in humans, it also treats cyanide poisoning. Non-professional sources also claim that it works for ammonia poisoning, but there is little medical literature to back this up. It is usually used to protect newly laid fish eggs from being infected by fungus. This is useful when the hobbyist wants to artificially hatch the fish eggs. For poisoning, injury (prevention of infection), or sickness, methylene blue is given as a "medicated bath" for the fish. Methylene blue is not without side effects to fish.
=== Industrial applications === Laccases have found a wide range of application, from food additive and beverage processing to biomedical diagnosis, and as cross‐linking agents for furniture construction or in the production of biofuels. The tyrosinase‐induced polymerization of peptides offers facile access to artificial mussel foot protein analogues. Next generation universal glues can be envisioned that perform effectively even under rigorous seawater conditions and adapt to a broad range of difficult surfaces.
== Partitioning methods == The most common method of measuring amino acid hydrophobicity is partitioning between two immiscible liquid phases. Different organic solvents are most widely used to mimic the protein interior. However, organic solvents are slightly miscible with water and the characteristics of both phases change making it difficult to obtain pure hydrophobicity scale. Nozaki and Tanford proposed the first major hydrophobicity scale for nine amino acids. Ethanol and dioxane are used as the organic solvents and the free energy of transfer of each amino acid was calculated. Non liquid phases can also be used with partitioning methods such as micellar phases and vapor phases. Two scales have been developed using micellar phases. Fendler et al. measured the partitioning of 14 radiolabeled amino acids using sodium dodecyl sulfate (SDS) micelles. Also, amino acid side chain affinity for water was measured using vapor phases. Vapor phases represent the simplest non polar phases, because it has no interaction with the solute. The hydration potential and its correlation to the appearance of amino acids on the surface of proteins was studied by Wolfenden. Aqueous and polymer phases were used in the development of a novel partitioning scale. Partitioning methods have many drawbacks. First, it is difficult to mimic the protein interior. In addition, the role of self solvation makes using free amino acids very difficult. Moreover, hydrogen bonds that are lost in the transfer to organic solvents are not reformed but often in the interior of protein.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.